Implications of a diagnosis of rheumatoid arthritis in resource-poor countries

• Published in: Best practice & research. Clinical rheumatology 2022-03, Vol.36 (1), p.101725-101725, Article 101725
• Main Authors: Yerima, Abubakar, Akintayo, Richard, Adebajo, Adewale
• Format: Article
• Language: English
• Subjects: Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - drug therapy; Biologic agents; Biological Products - therapeutic use; Health disparities; Humans; Infections; Quality of Life; Resource-poor settings; Rheumatoid arthritis; Rheumatologists
• ISSN: 1521-6942; 1532-1770
• DOI: 10.1016/j.berh.2021.101725

Rheumatoid arthritis (RA) is a multisystemic autoimmune disease that predominantly affects synovial joints. It causes marked disability, reduces health-related quality of life, and leads to high mortality. The diagnosis of RA is often made by standard criteria, and the management of this condition is usually undertaken according to the established guidelines. In resource-poor settings, the diagnosis and management of RA are hampered by diverse factors such as late presentation, inadequate trained personnel, poor healthcare infrastructure, low socioeconomic status, poor access to both conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologics, and a high burden of infectious diseases such as tuberculosis, hepatitis, and human immunodeficiency virus. There is a need to establish registries in these settings to provide adequate information on the pattern, medication, and long-term outcome of RA in resource-poor countries in order to provide a practical and evidence-based management guide for rheumatologists, which is appropriate for these settings.